Inventor · disambiguated record
Jay Mei
Also filed as: MEI JAY · MEI JAY M
6 granted patents·18 pending applications·7 citations·filing 2003–2025
72Inventor score
Files withCELGENE AVILOMICS RES INC8ANTENGENE BIOLOGICS LTD6ANTENGENE DISCOVERY LTD4JANSSEN PHARMACEUTICA NV2CELGENE CAR LLC1
Top patents by PatentIndex Score
24 records- 0169US9364476B2Methods of treating a Bruton's Tyrosine Kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2012·Granted Jun 14, 2016·1 cites·26 claims
- 0269US7196110B2N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disordersJANSSEN PHAMACEUTICA N V·Filed 2003·Granted Mar 27, 2007·6 cites·37 claims
- 0367US12312357B2PRMT5 inhibiting compounds and uses thereofANTENGENE DISCOVERY LTD·Filed 2024·Granted May 27, 2025·0 cites·3 claims
- 0459US9492471B2Methods of treating a disease or disorder associated with Bruton'S Tyrosine KinaseCELGENE AVILOMICS RES INC·Filed 2013·Granted Nov 15, 2016·0 cites·16 claims
- 0558US2025361295A1Novel anti-lilrb4 antibodies and uses thereofANTENGENE BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 0656US7816390B2N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2008·Granted Oct 19, 2010·0 cites·2 claims
- 0756US7795440B2N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disordersJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Sep 14, 2010·0 cites·2 claims
- 0853US2024400689A1Novel anti-cd276 antibodies and the uses thereofANTENGENE BIOLOGICS LTD·Filed 2022·Application pending·0 cites
- 0953US2025368734A1Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereofANTENGENE BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 1052US2024052052A1Novel anti-cd24 antibodiesANTENGENE BIOLOGICS LTD·Filed 2022·Application pending·0 cites
- 1152US2025223358A1Novel anti-cd3 antibodies and uses thereofANTENGENE BIOLOGICS LTD·Filed 2023·Application pending·0 cites
- 1250US2023095569A1Antibodies and methods for treating claudin-associated diseasesANTENGENE BIOLOGICS LTD·Filed 2021·Application pending·0 cites
- 1349US2025206749A1Prmt5 inhibiting compounds and uses thereofANTENGENE DISCOVERY LTD·Filed 2025·Application pending·0 cites
- 1449US2023212170A1Inhibitors of kras g12c protein and uses thereofSHANGHAI ANTENGENE CORPORATION LTD·Filed 2021·Application pending·0 cites
- 1548US2017216432A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE CAR LLC·Filed 2016·Application pending·0 cites
- 1646US2023295166A1Atr inhibitors and uses thereofANTENGENE DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 1745US2014142128A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 1845US2015139979A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 1945US2023339927A1Atr inhibitors and uses thereofANTENGENE DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 2045US2016287588A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 2145US2015064172A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 2244US2005130910A1Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targetsFiled 2004·Application pending·0 cites
- 2340US2014140991A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 2437US2014142129A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jay Mei files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →